Challenges In Valuing The Impact Of Sexually Transmitted Infections

Published Jan 23, 2014
Birmingham, United Kingdom - Sexually transmitted infections like chlamydia are a global public health concern. Chlamydia can cause infertility and other reproductive tract problems in women. Health policy decision makers need to know which interventions they should prioritise to get the best value from the resources available for the prevention and control of sexually transmitted infections. Researchers at the University of Birmingham, with support from a clinical expert at the University of Bern, Switzerland, reviewed studies examining the health impacts of chlamydia infections and their complications. The researchers found that there was a lack of evidence to inform economic evaluations in this area. They suggested that future cost-effectiveness studies need to highlight the lack of primary data available and examine more fully the methodological challenges involved in valuing health states for chlamydia. Tracy Roberts, who designed the study, said: "Researchers and policy makers need to pay more attention to the impact of sexually transmitted infections on health and quality of life. Our study shows major gaps in our knowledge about this important area of human health. Our findings contribute to debates about the methods we should use to value health outcomes. Addressing these issues is crucial to ensuring that policy makers are fully informed when making funding decisions." The full study "Valuing the Health States Associated with Chlamydia trachomatis Infections and Their Sequelae: A Systematic Review of Economic Evaluations and Primary Studies," is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×